CD16 and 17 phase 3 trials are firmly established with a legitimate CRO, dozens of trial sites (23 in critical and 27 in severe) and now the much-needed flood of patients in Brazil. Furthermore, efficacy in severe and critical Covid will be compelling for an EUA/approval.

Waiting on LH, for which a phase 3 trial has not even been approved will put us into 2023.

Brazilian trials are are our quickest route to EUA/approval.